Introduction
Ligand-gated ion channels (LGICs) play vital roles in regulating neuronal excitation and inhibition in animals. These channels are either (1) cation-selective channels, the activation of which depolarizes the postsynaptic membrane towards firing an action potential, or (2) anion-selective channels, the activation of which hyperpolarizes the membrane or suppresses the depolarization generated by cation channels (Smart and Paoletti, 2012) . Nicotinic acetylcholine receptors and γ-aminobutyric acid (GABA) receptors, which are members of the Cys-loop family of LGICs, are examples of such cation and anion channels, respectively (Miller and Smart, 2010) . Inhibitory glutamate receptors, which are found only in invertebrates, are also Cys-loop LGIC family members.
The Cys-loop LGICs are pentamers, the subunits of which are assembled to form a central ion-permeable channel. Each subunit consists of a large N-terminal extracellular domain, four hydrophobic α-helical transmembrane segments (TMs), an intracellular loop between TM3 and TM4, and a short extracellular C-terminus. The orthosteric agonistbinding site is located at the subunit interface of the extracellular domain. These channels are important targets for drugs and insecticides (Alexander et al., 2015; Ozoe, 2013) .
Glutamate-gated chloride channels (GluCls) are the main targets for the insecticidal, acaricidal, and nematicidal macrolides avermectins (AVMs), which allosterically activate and modulate various ion channels, including GABA-gated chloride channels (GABACls), glycine-gated chloride channels, pH-gated chloride channels, α7 acetylcholine-gated cation channels, ATP-gated P2X receptor cation channels, and G protein-gated inwardly rectifying potassium channels (Chen et al., 2017; Cully et al., 1994; Cully et al., 1996; Dawson et al., 2000; Fuse et al., 2016; Krause et al., 1998; Nakatani et al., 2016; Shan et al., 2001; Silberberg et al., 2007) . GluCls are activated by Abamectin (AVM B1) is used to control phytophagous mites and insect pests on agricultural and horticultural crops (Lasota and Dybas, 1991) . Ivermectin (IVM) (Fig. 1) , C22-23-dihydro AVM B1, is widely used to control endo-and ectoparasites in animals and to treat onchocerciasis and lymphatic filariasis caused by parasitic worms in humans (Laing et al., 2017; Ōmura and Crump, 2014; Wolstenholme et al., 2016) . GABACls are targets for chlorinated hydrocarbon and phenylpyrazole insecticides, which stabilize the closed conformation of GABACls by interacting with TM2 amino acid residues on the cytoplasmic side within the channel pore (Ozoe, 2013) . Isoxazoline and mbenzamidobenzamide insecticides are new-generation antagonists that inhibit insect GABACls (Asahi et al., 2015; Gassel et al., 2014; McTier et al., 2016; Nakao and Banba, 2016; Nakao et al., 2013; Ozoe et al., 2010; Ozoe et al., 2013; Shoop et al., 2014) . These insecticides inhibited GABACls with mutations conferring insensitivity to the conventional antagonists Asahi et al., 2015) . The substitution of a conserved TM3 Gly located in the transmembrane subunit interface (TSI) of Drosophila GABACls diminished or eliminated the inhibitory effects of a m-benzamidobenzamide (meta-diamide) insecticide on GABA responses, whereas the conventional antagonists remained effective . These findings indicate that these insecticides have mode(s) of action distinct from that of the conventional channel-blocking antagonists.
Fluralaner (Bravecto TM ) (Fig. 1) is a recently marketed isoxazoline ectoparasiticide that is used for flea and tick protection in pets (Taenzler et al., 2014; Wengenmayer et al., 2014) . This compound inhibits agonist responses in both GABACls and GluCls, with selectivity for the former over the latter (Ozoe et al., 2010) , whereas IVM is a selective This article has not been copyedited and formatted. The final version may differ from this version. activator or modulator for GluCls (Fuse et al., 2016) . In the present study, we sought to identify the mechanism underlying the difference in fluralaner and IVM sensitivity between GluCls and GABACls. We report that the substitution of a single amino acid in the TSI of GluCls with a positionally equivalent amino acid from GABACls results in a drastic increase in the antagonist potency of fluralaner and a dramatic elimination of the IVM activation of currents and the IVM potentiation of the glutamate responses.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Chemicals. Fluralaner (99%), A1209 (99%), and A341 (99%) were synthesized according to a previously reported method (Mita et al., 2005 (Mita et al., , 2009 . GABA and IVM (B1a ≥90%, B1b ≤5%) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Other general chemicals including sodium hydrogen L-glutamate were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan), unless otherwise noted. (100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.6) for 1-2 h at 20 °C.
After the treatment, the oocytes were washed with Ca 2+ -free SOS supplemented with 2.5 mM sodium pyruvate, gentamycin (50 μg/ml; Thermo Fisher Scientific, Waltham, MA, USA), penicillin (100 U/ml; Thermo Fisher Scientific), and streptomycin (100 μg/ml; Thermo Fisher Scientific) and incubated for 1-2 days at 16 °C.
The Musca GluCl and Rdl cDNAs containing a T7 promoter site upstream of the This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) . Although this mutation may allosterically affect glutamate binding to the orthosteric site, the dose-response curve indicated that the channel functioned normally to induce currents in response to glutamate.
Fluralaner inhibition of glutamate-induced currents in mutant GluCls.

Fluralaner inhibited glutamate-induced currents in wild-type Musca GluCls expressed in
Xenopus oocytes (Fig. 3B,D) , with an IC50 of 146 nM (Table 1) . However, wild-type Musca GluCls were ≈24-fold less sensitive to fluralaner than were wild-type Musca GABACls, as previously reported (Ozoe et al., 2010) . Fluralaner was ≈2-fold less potent toward the I253A mutant than in the wild-type GluCl, whereas it was ≈4-fold and ≈2-fold more potent in the M257L and M257L/T316V mutants, respectively, than in the wildThis article has not been copyedited and formatted. The final version may differ from this version. type GluCl ( Fig. 3D ; Table 1 ). The potency of fluralaner in the T316V mutant did not differ significantly from that in the wild type. Notably, the L315F mutant was strongly inhibited by fluralaner, with an IC50 of 1.06 nM, indicating that this mutant is ≈138-fold more sensitive to fluralaner inhibition than the wild type ( Fig. 3C,D ; Table 1 ). The IC50 of fluralaner in the L315F mutant was even ≈6-fold smaller than its IC50 in the inhibition of GABA-induced currents in Musca GABACls ( Fig. 3D ; Table 1 ).
IVM actions on mutant GluCls. IVM alone activated slow, irreversible currents in wild-type Musca GluCls expressed in Xenopus oocytes ( Fig. 4A) , with an EC50 of 18.8 nM ( Table 1 ). The wild-type Musca GluCls were ≈66-to ≈184-fold more sensitive to IVM than were wild-type Musca GABACls (Table 1 ). The potency of IVM was ≈5-fold higher in the I253A mutant than in the wild type, whereas the potencies of the M257L and T316V mutants were not significantly different from that of the wild-type GluCl ( Fig.   4C ; Table 1 ). The difference in the maximal current amplitude between the wild type and mutants could be ascribed to differences in the expression levels of channels in oocytes (Fig. 4C) . Surprisingly, the L315F mutant, which showed an enhanced sensitivity to fluralaner, lacked sensitivity to IVM in terms of activation (Fig. 4B,C) . Next, we examined IVM potentiation and antagonism of glutamate-induced currents in the L315F mutant because IVM exerts a triple action on GluCls and GABACls depending on the conditions (Fuse et al., 2016) . In L315F GluCls, IVM did not potentiate the currents induced by a low concentration of glutamate (EC5, 50 μM) (Fig. 5A ,B) but inhibited those induced by a high concentration of glutamate (EC90, 3 mM), with an IC50 of 5.48 ± 1.20 nM (SEM, n = 6), which is not significantly different from the IC50 (4.92 ± 2.23 nM) for the wild type (Fig. 5C,D) .
Effects of fluralaner analogs on L315F mutant GluCls. As fluralaner showed
This article has not been copyedited and formatted. The final version may differ from this version. marked antagonism of the L315F GluCl, we examined whether a similar potency enhancement could be observed for fluralaner analogs ( Fig. 6; Fig. 7 ). The isoxazolines A1209 and A341 (Fig. 1) are fluralaner analogs that show >500-fold and >100-fold higher antagonism of Musca GABACls, respectively, compared with Musca GluCls (Fig.   6A ,B,D; Fig. 7A ,B,D; Table 1 ). The L315F mutation resulted in >6000-and >100-fold enhancement of the potency of A1209 and A341 in GluCls ( Fig. 6C,D ; Fig. 7C ,D; Table   1 ), which were, respectively, much greater than and comparable to the enhancement observed for fluralaner. The L315F GluCl was outstandingly sensitive to A1209.
Although the isoxazoline A341 exhibited little antagonism in wild-type GluCls, the antagonist potency of this compound in L315F GluCls was comparable to that in wildtype GABACls (Fig. 7) .
Effects of aromatic amino acid substitution at position 315 on the potency of fluralaner. As the L315F substitution enhanced the potency of fluralaner against Musca GluCls, we examined the effects of other amino acid substitutions on the potency of fluralaner (Fig. 8) . We injected cRNAs encoding five mutants (L315Y, L315W, L315H, L315A, and L315M) into oocytes. The aromatic amino acids included Tyr, Trp, and His, which has the aromatic heterocycle imidazole in the side chain. Ala and Met were chosen as hydrophobic aliphatic amino acids. Although the oocytes injected with the cRNAs for L315W and L315A failed to respond to glutamate, the other oocytes did respond to glutamate (Fig. 8A ). Fluralaner inhibition of glutamate-induced currents was ≈24-fold and ≈8-fold more potent in the L315Y and L315H mutants, respectively, than in the wild type (Fig. 8B ,C,E; Table 1 ). In contrast, the potency of fluralaner did not differ significantly between the L315M mutant and the wild-type channel ( Fig. 8E ; Table 1 ).
These findings indicate that aromatic amino acids at position 315 are effective in This article has not been copyedited and formatted. The final version may differ from this version. Effects of aromatic amino acid substitution at position 315 on the potency of IVM. We examined the effects of the L315Y, L315H, and L315M substitutions on IVMinduced currents in Musca GluCls (Fig. 9) . The former two substitutions abolished the IVM-induced activation of Musca GluCls (Fig. 9A,B,D) . In contrast, IVM activated currents in the L315M mutant, although the potency was ≈2-fold lower than in the wildtype channel ( Fig. 7C,D ; Table 1 ). These findings indicate that aromatic amino acids, but not an aliphatic amino acid, at position 315 eliminate the IVM-induced activation of
GluCls.
This article has not been copyedited and formatted. The final version may differ from this version. , 2017) . Furthermore, G36' mutations were reported to diminish or eliminate the ability of a meta-diamide insecticide to inhibit GABA-induced currents in the Drosophila GABACls . Interestingly, the analogous mutation of a positionally equivalent Gly was identified in the nicotinic acetylcholine receptor α7 subunit of spinosad-resistant western flower thrips (Frankliniella occidentalis) and the nicotinic acetylcholine receptor α6 subunit of spinosad-resistant tomato leafminers (Tuta absoluta) (Puinean et al., 2013; Silva et al., 2016) . Together, these reports indicate that a This article has not been copyedited and formatted. The final version may differ from this version. conserved Gly in TM3 plays a key role and that the TSI seems to form the sites of action for a variety of ligands.
The ectoparasiticide fluralaner was shown to exhibit selective antagonism of GABACls over GluCls (Ozoe et al., 2010) . To examine whether any amino acid substitution enhances the low potency of fluralaner in GluCls, we focused on replacing amino acids around G36' in the TSI of Musca GluCls with the positionally equivalent amino acids of Musca GABACls, which were sensitive to fluralaner (Table 1) . We have shown that the substitution of an amino acid, Leu315, located one α-helical turn below G36', with aromatic amino acids (but not with an aliphatic amino acid) dramatically enhances the potency of fluralaner (Fig. 8) . These findings may explain the high potency of fluralaner in GABACls, which possess Phe at the equivalent position. Our docking simulation of the S enantiomer of fluralaner, which is the active component (Ozoe et al., 2010) , to a Musca GluCl homology model revealed that the aromatic ring of fluralaner lies near Leu315 (Fig. 10) . It remains to be clarified whether the enhanced potency depends on a π-π stacking interaction (Zhao et al., 2015) between the aromatic ring of substituted amino acids at position 315 and the phenyl group of fluralaner.
In contrast to the enhancement of the potency of fluralaner, we found that the same aromatic substitution abolished the direct IVM activation of GluCls and the IVM potentiation of glutamate-induced currents, while the antagonism remained unchanged (Fig. 5,9 ). The L315M mutant, which has a non-aromatic amino acid at position 315, retained the ability to be activated by IVM. This finding is consistent with the fact that the homomeric AVM-sensitive C. elegans GluCl-α channel has Met at an equivalent position, whereas the AVM-insensitive β channel has Gln at this position (Cully et al., 1994 ) ( Supplementary Fig. 1 ). It will be interesting to investigate whether this Gln is This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2) , adjacent to Leu315, is positionally equivalent to the amino acid that was reported to form a hydrogen bond with IVM in an X-ray crystal study of the C. elegans
GluCl-α channel (Hibbs and Gouaux, 2011). The T316V substitution did not change the potency of IVM in the present study, suggesting that the hydrogen bonding does not contribute substantially to IVM binding in Musca GluCls. Instead, our data suggest that Leu315 is located adjacent to bound IVM. How the substitution of the amino acid Leu315 impairs the IVM-induced activation of GluCls and the IVM-induced potentiation of glutamate responses remains to be examined.
Finally, we generated the Musca RDL subunit with an inverse mutation (the substitution of Phe with Leu at an equivalent position ( Fig. 2A) ) to evaluate whether this mutation results in low sensitivity of GABACls to fluralaner. However, because this mutation led to a spontaneously open channel, we were unable to determine the potency of fluralaner in this mutant.
In conclusion, we have shown that Leu315 located in the TSI of Musca GluCls and the positionally equivalent amino acid of GABACls play key roles in determining the selectivity of fluralaner and IVM toward these channels. This finding may be applicable to other GluCls and GABACls, given that the TM3 sequence is highly conserved among insect and mite species (Supplementary Fig. 1 ). As predicted, a very recent publication has indicated that activation by IVM was strongly reduced and that activation by okaramine B, an insecticidal indole alkaloid, was completely abolished in the silkworm (Bombyx mori) GluCl containing an L319F mutation, which is equivalent to the L315F mutation in the Musca GluCl (Furutani et al., 2017) . More importantly, we have shown in the present study that the L315F mutation has opposite impacts on the selectivity of This article has not been copyedited and formatted. The final version may differ from this version. with an equivalent mutation emerge, these arthropod pests would be sensitive to fluralaner.
These findings should prove useful for understanding the mode of action of these parasiticides and further development of pest control agents.
Authorship Contributions
Participated in research design: Nakata, Asahi, Nakahira, F. Ozoe, and Y. Ozoe.
Conducted experiments: Nakata, Fuse, Yamato, and F. Ozoe.
Performed data analysis: Nakata, Fuse, and Yamato.
Wrote or contributed to the writing of the manuscript: Nakata, Fuse, and Y. Ozoe.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
